What is HC Wainwright’s Estimate for COYA Q1 Earnings?

Coya Therapeutics, Inc. (NASDAQ:COYA) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Coya Therapeutics in a research report issued on Monday, March 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.46) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The firm had revenue of $3.96 million during the quarter, compared to analyst estimates of $1.93 million.

A number of other research firms also recently issued reports on COYA. D. Boral Capital restated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Monday, March 16th. Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Monday, March 16th. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $4.20 on Tuesday. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $7.75. The business has a 50 day moving average price of $4.66 and a 200 day moving average price of $5.47. The company has a market capitalization of $98.52 million, a P/E ratio of -3.31 and a beta of 0.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC increased its stake in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after buying an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new position in Coya Therapeutics during the 2nd quarter valued at $119,000. JPMorgan Chase & Co. bought a new position in Coya Therapeutics during the 3rd quarter valued at $28,000. CM Management LLC grew its holdings in Coya Therapeutics by 50.0% during the 3rd quarter. CM Management LLC now owns 300,000 shares of the company’s stock worth $1,710,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Dauntless Investment Group LLC increased its position in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock worth $872,000 after purchasing an additional 101,932 shares during the last quarter. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

Coya Therapeutics News Summary

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained an $18 price target on COYA, a signal of analyst conviction that can support investor demand. HC Wainwright Reiterates “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)
• Positive Sentiment: HC Wainwright nudged its Q4 2026 estimate slightly higher (from ($0.46) to ($0.43) EPS), a modest improvement for late-2026 profitability expectations that could be viewed positively by investors.
• Neutral Sentiment: HC Wainwright published multi-year forecasts (Q1–Q4 2027 and FY2027 EPS of around ($1.66)); these longer-horizon projections provide context but are farther out and less likely to move the stock near term.
• Neutral Sentiment: Public short-interest postings in March show “0 shares” and NaN changes — an apparent data/reporting anomaly. That reduces the usefulness of the short-interest signal for explaining price moves today.
• Negative Sentiment: HC Wainwright cut several near-term 2026 EPS forecasts: Q1 (to ($0.39) from ($0.33)), Q2 (to ($0.39) from ($0.33)), Q3 (to ($0.41) from ($0.40)) and lowered FY2026 to ($1.64) from ($1.52). These downgrades reflect weaker near-term profitability expectations and likely weigh on sentiment.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.